Patrick K Reville, MD, MPH
Department of Leukemia, Division of Cancer Medicine
About Dr. Patrick K Reville
I am a clinician scientist and Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center. My research is focused on understanding the complex interactions of the human immune system with leukemias with the ultimate goal to translate this knowledge into the development of novel, rationally targeted therapeutics to improve the outcomes of leukemia patients. My clinical focus is in caring for and treating patients with chronic and acute leukemias. Additionally, I am passionate about shared decision making and effective patient-doctor communication.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2017 | University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, MD, Medicine |
| 2011 | The Ohio State University, Columbus, OH, USA, MPH, Public Health |
| 2009 | The Ohio State University, Columbus, OH, USA, BS, Microbiology |
Postgraduate Training
| 2019-2022 | Clinical Fellowship, Hematology & Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2018-2019 | Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX |
| 2017-2018 | Clinical Internship, Internal Medicine, Baylor College of Medicine, Houston, TX |
Board Certifications
| 2022 | Medical Oncology |
| 2022 | Hematology |
| 2021 | Internal Medicine |
Honors & Awards
| 2022 | Waun Ki Hong Award for Achievement in Basic Science Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
| 2022 | Journal of Clinical Oncology Young Investigator Award, Conquer Cancer Foundation |
| 2022 | Lymphoma Research Foundation Lymphoma Scientist Research Mentoring Program (LSRMP) – Translational Scholar, Lymphoma Research Foundation |
| 2021 | ASH Abstract Achievement Award, American Society of Hematology |
| 2017 | Dylan Cappel Memorial Scholarship Grantee, University of Wisconsin School of Medicine and Public Health |
Selected Publications
Peer-Reviewed Articles
- Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res. e-Pub 2023. PMID: 37163233.
- Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):JCO2102823, 2022. e-Pub 2022. PMID: 35704787.
- Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
- Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. PMID: 35483396.
- Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
- Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
- Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma 62(14):3402-3410, 2021. e-Pub 2021. PMID: 34380367.
- Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
- Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. PMID: 34329576.
- Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
- Abbas HA, Reville PK, Jiang X, Yang H, Reuben A, Im JS, Little L, Sinson JC, Chen K, Futreal A, Garcia-Manero G. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. Front Immunol 12:659625, 2021. e-Pub 2021. PMID: 33912187.
- Reville PK, Kadia T. Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia. Curr Treat Options Oncol 21(4):34, 2020. e-Pub 2020. PMID: 32318829.
- Reville PK, Kadia TM. Maintenance Therapy in AML. Front Oncol 10:619085, 2020. e-Pub 2021. PMID: 33604298.
- Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer 7(1):70, 2019. e-Pub 2019. PMID: 30871628.
- Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res 24(1):189-196, 2018. e-Pub 2017. PMID: 28972044.
- Parajuli S, Reville PK, Ellis TM, Djamali A, Mandelbrot DA. Utility of protocol kidney biopsies for de novo donor-specific antibodies. Am J Transplant 17(12):3210-3218, 2017. e-Pub 2017. PMID: 28805293.
- Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Front Immunol 8:675, 2017. e-Pub 2017. PMID: 28659916.
- Lesinski GB, Reville PK, Mace TA, Young GS, Ahn-Jarvis J, Thomas-Ahner J, Vodovotz Y, Ameen Z, Grainger E, Riedl K, Schwartz S, Clinton SK. Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells. Cancer Prev Res (Phila) 8(11):1036-44, 2015. e-Pub 2015. PMID: 26276751.
- Askar M, Hsich E, Reville P, Nowacki AS, Baldwin W, Bakdash S, Daghstani J, Zhang A, Klingman L, Smedira N, Moazami N, Taylor DO, Starling RC, Gonzalez-Stawinski G. HLA and MICA allosensitization patterns among patients supported by ventricular assist devices. J Heart Lung Transplant 32(12):1241-8, 2013. e-Pub 2013. PMID: 24075503.
- Edinur HA, Dunn PP, Hammond L, Selwyn C, Brescia P, Askar M, Reville P, Velickovic ZM, Lea RA, Chambers GK. HLA and MICA polymorphism in Polynesians and New Zealand Maori: implications for ancestry and health. Hum Immunol 74(9):1119-29, 2013. e-Pub 2013. PMID: 23792058.
- Reville P, Zhao C, Perez T, Nowacki AS, Phillips D, Bowen G, Starling N, Pflaum B, Strickland R, Fung J, Askar M. A student leadership model for promoting educational programs in organ donation and transplantation. Transplant Proc 45(4):1287-94, 2013. PMID: 23726553.
- Cummings HE, Barbi J, Reville P, Oghumu S, Zorko N, Sarkar A, Keiser TL, Lu B, Rückle T, Varikuti S, Lezama-Davila C, Wewers MD, Whitacre C, Radzioch D, Rommel C, Seveau S, Satoskar AR. Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. Proc Natl Acad Sci U S A 109(4):1251-6, 2012. e-Pub 2012. PMID: 22232690.
Other Articles
- 1. Reville, PK, Sheikh I, Choi A, Dai E, Henderson J, Li X, Rojas E, Le C, Okwuchi C, Devonish M, Carrio R, Pate N, Malley K, Bangari D, Givigan J, Shi C, Liu B, Byers T, Westin J, Ahmed S, Fowler N, Fayad L, Lee H, Nastoupil L, Sassoon I, Cucchetti M, Wang R, Agarwal M, Abbadessa G, Meng R, Meibalan E, Powers L, Cao J, Ying X, Balko K, Yu Q, Jiao J, Cortez-Retamozo V, Sidhu S, Shaffer D, Neelapu S, Wang L, Li A, Green MR CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin. BioRxiv, 2023.
Book Chapters
- Parajuli S, Reville PK. End Stage Renal Disease – Treatment Options: Dialysis Versus Transplant. In: Kidney Transplant Management. Springer, Cham, 2019.
Grant & Contract Support
| Title: | CD38 as a Targetable Antigen in Large B Cell Lymphoma (LBCL) to improve the efficacy CD19 Directed Chimeric Antigen Receptor T (CAR T) Cell Therapy and Mitigate CD19 Negative Relapse |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | CD38 as a Targetable Antigen in Large B Cell Lymphoma Combined with CD19 CAR T Cells |
| Funding Source: | Lymphoma Research Foundation |
| Role: | Principal Investigator |
| Title: | CD38 as a Targetable Antigen in Large B Cell Lymphoma Combined with CD19 CAR T Cells |
| Funding Source: | Lymphoma Research Foundation |
| Role: | Principal Investigator |
| Title: | Defining Biomarkers and Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Large B-cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified November 08, 2023